total revenue vs non-gaap ep vs
consensu due larg hiv destock guidanc product sale
reiter gilead remain hope hcv busi stabil around
chang model reduc dcf-base price target
world-wide hiv sale q/q y/i consensu
gilead note particularli larg reduct sub-wholesal
inventori hcv sale q/q y/i also consensu
in-lin total revenu q/q y/i
vs estim consensu gilead report non-gaap gross
margin vs non-gaap sg expens
revenu revenu vs respect
non-gaap ep q/q y/i consensu
gilead reiter guidanc includ net product sale gross margin
 expens sg expens
product sale estim remain though ep estim decreas
dcf-base price target decreas
hiv sale q/q y/i consensu
weak due perform gilead busi q/q
y/i vs demand trend busi remain strong
prescript y/i ex viread howev report revenu advers
impact particularli larg reduct sub-wholesal inventori although
histor experienc inventori drawdown follow annual hiv price
increas year sizabl past due two addit factor
elimin viread inventori due avail gener tdf decreas
stock anticip biktarvi approv gilead suggest absent addit
factor hiv revenu would grown line prescript y/i impli
addit inventori reduct seen histor
biktarvi launch solid start trajectori far
compar genvoya gilead report revenu week
biktarvi avail note approxim one-half revenu due end-us
demand demand larg driven switch regimen includ
patient dolutegravir regimen consult suggest base
ph data biktarvi becom clear first choic regimen approv biktarvi
eu expect follow posit recommend chmp
april gilead report taf-bas regimen account gilead hiv
prescript volum slightli end project
launch taf-bas regimen grow hiv franchis despit
launch tdf gener hiv franchis estim y/i vs prior
pleas see page report import disclosur
gilead market leader treatment hiv hcv acquir car-t
oncolog platform kite expect combin launch new
taf-bas combin pill hiv market growth share gain price increas
hiv franchis sale grow compound-annual-growth-rate despit viread patent
expir gilead hcv franchis struggl declin patient volum new
competit erod sale project gilead hcv franchis gener world-wide
sale declin expect partial off-set pipelin program includ
yescarta filgotinib base dcf analysi gilead stock under-valued
interim futil analysi filgotinib phase
uc
possibl eu approv biktarvi
possibl approv yescarta
aggress nhl eu
hcv sale
hiv franchis grow
despit expir
rest pipelin product
exce project
launch taf-bas pill allow
hiv franchis grow
expir tenofovir patent
candid pipelin
hcv sale fail achiev forecast
hiv franchis fail meet
project due competit major
chang treatment paradigm
gilead pipelin busi
develop effort fail produc
product capabl drive meaning
revenu earn
gilead develop market treatment hiv hbv hcv fungal infect
acquir car-t oncolog platform kite gilead antivir portfolio biggest
revenu driver hcv franchis led sofosbuvir nucleosid inhibitor result
phase trial sofosbuvir-bas regimen shown potent well
toler high barrier viral resist expect hcv franchis maintain
revenu gilead lead hiv franchis anchor tenofovir well-
toler efficaci nucleotid analog gilead develop sever tenofovir-
base combin pill includ truvada atripla complera stribild genvoya odefsey
descovi togeth captur share treatment-na hiv patient drive
hiv franchis revenu project revenu
hcv price market share expect stabil
 hcv revenu q/q y/i ex-u hcv revenu
q/q y/i experienc substanti sequenti declin due competit
mavyret medicar contract gone effect januari
q/q decreas net price per patient gilead believ price stabil though
gilead continu lose share percentag point q/q week
manag continu expect share plateau around gilead hope
stabl predict busi price share consist slow
steadi declin hcv market patient start manag reiter hcv guidanc
hcv estim materi unchang
gilead record revenu yescarta first full quarter market well
ahead consensu estim gilead continu suggest yescarta
ramp measur center train cancer center
author treat patient gilead anticip center treat yescarta-
elig patient patient approv gilead note
patient cover commerci ff plan approxim cover
medicar approv yescarta eu continu anticip
yescarta uptak strong increas yescarta estim
clinic trial yescarta continu pivot phase studi line dlbcl
phase ii studi combin initi pivot
phase ii yescarta r/r indol nhl set complet enrol
addit gilead expect complet enrol pivot ph ii
construct yescarta differ manufactur mcl
initi pivot phase ii adult pediatr
gilead also highlight recent progress pipelin develop inflamm five
phase studi filgotinib on-going rheumatoid arthriti ulcer coliti
crohn diseas phase trial ra fulli enrol finch data
finch expect later year data readout expect
phase ii studi filgotinib inflammatori diseas also on-going
interim futil analysi phase studi filgotinib uc expect
decemb gilead file ind intern develop small molecul
inflammatori condit clinic develop expect begin come
result selorsertib stellar stellar phase nash
anticip gilead also conduct phase ii combin studi selonsertib
inhibitor fxr agonist patient nash proof
concept data combin studi present european associ
studi liver annual meet april phase iib combin studi
investor desper wait gilead revenu trough two year declin
look sign gilead pois re-rat gilead revenu ep
miss consensu estim quarter signal turn
gilead fundament said also find gilead perform
overli disappoint revenu declin due viread gener hcv competit
anticip shortfal due mostli destock gilead hiv busi
short-term issu prescript gilead continu franchis y/i
demand trend fundament busi remain strong fact biktarvi earli
launch suggest help gilead regain share dolutegravir regimen hiv remain
bright spot despit issu q/q declin hcv sale steep ugli
in-lin estim manag remain hope hcv stabil mid-
year though yescarta revenu remain round error rest gilead busi
perform impress increas estim make
us hope meaning contributor futur all-in-al suggest
cut price target long-term project adjust
dramat gilead trade project free cash flow
yield continu believ under-valued cash flow
gilead develop market treatment hiv hbv hcv fungal infect
gilead antivir portfolio largest revenu driver next sever
year gilead lead hiv franchis anchor tenofovir well-toler
gener revenu captur share patient newli initi
hiv therapi tenofovir disoproxil fumar viread lost patent
protect gilead develop second gener version tenofovir
alafenamid taf improv safeti extend patent protect
project sale gilead hiv franchis grow
launch new patent-protect combin pill biktarvi bic/f/taf
genvoya e/c/f/taf descovi f/taf odefsey e/r/taf taf
regimen extend commerci life franchis gilead hcv franchis built
around sovaldi nucleosid inhibitor whose potenc high barrier resist
made cornerston market-lead all-or hcv combin
sovaldi launch decemb eu januari
approv gilead harvoni sofosbuvir ledispavir octob
brought first fda-approv interferon free regimen genotyp hcv
patient largest hcv popul hcv franchis got fast
start post revenu unfortun best day
gilead hcv franchis past emerg competit gild hcv
franchis gener revenu estim continu
declin gilead recent expand oncolog franchis
acquisit kite gilead gain yescarta car-t therapi
anhl approv fda octob well lead car-t
platform cowen project yescarta achiev revenu third line
anhl hope gilead trough earn final
sight two year rapid declin hcv revenu project non-gaap
ep non-gaap ep declin compound-annual-growth-rate gilead
current trade forward pe project cash flow
yield base dcf analysi gilead stock under-valued
initi pivot phase ii adult zuma
complet phase ii filgotinib psoriat arthriti
interim analysi phase trial filgotinib ulcer coliti
possibl eu approv yescarta aggress nhl
potenti eu approv b/f/taf
year follow-up data zuma
data phase ii studi fxr agonist nash
complet phase ii studi filgotinib ankylos spondyl
phase ii data tirabrutinib idelalisib entospletinib r/r cll
complet enrol ph ia mage solid tumor
file ind tcr target solid tumor
complet enrol phase ii combo zuma
result filgotinib finch studi ra
complet enrol phase ii mcl zuma
initi pivot phase ii ped zuma
initi phase cll zuma
complet enrol ph ia studi anti-bcma mm
initi pivot phase ii yescarta r/r indol nhl zuma
decis registr studi anti-bcma base phase data
potenti chines launch sovaldi harvoni
data phase data selonsertib nash stellar
data filgotinib finch studi ra
data phase ii sjogern syndrom
phase ii data cutan lupu erythematosu
data filgotinib finch studi ra
complet phase ii ebola
data phase studi selonsertib nash stellar
complet phase trial descovi prep
interim data combin studi nash
complet enrol filgotinib divers studi crohn diseas
complet phase studi hiv cure
cowen compani
cowen compani
total hiv total hcv ranexa product contract comp in-process acquisit cost total sale asset interest incom loss attribut non-controlling net gaap fa net income/ loss ex fa forma ep ex fa share cowen
cowen compani
total hiv total hcv ranexa duct contract incom loss attribut non-controlling fa income/ loss ex fa forma ep ex fa share cowen
statement flow mm
cowen compani
depreci amort stock comp tax benefit employe stock chang net work capit ex cash provid use oper purchas /sale/matur market capit issuanc note acquisit net cash cash provid use invest proce issuanc of/ repurchas common proce issuanc of/ repurchas payment cash provid financ exchang rate chang increas decreas cash cash cash equival begin cash equival end summari oper exclud non-recur item cowen
cowen compani
financi year growth growth growth ranexa contract tax asset utilizedtax ratetax payment debtapprox free year growth ratetermin valu termin valu balanc dilut share per fulli dilut valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
gilead develop commerci drug number indic includ hiv hcv
hbv influenza cancer pulmonari hypertens forecast sale product
difficult outlook could alter new safety/efficaci find emerg
competit alter medic treatment paradigm chang pricing/
reimburs environ gilead stock price could also impact chang
outlook key pipelin program evalu market potenti drug
yet approv particularli riski moreov market exclus
gilead franchis depend patent subject challeng gener
drugmak valu gilead franchis could diminish lose
protect key patent
